Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. (STOK) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
stok · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Stoke Therapeutics, Inc. (STOK) measures how much investors pay for each dollar of the company's trailing earnings. STOK's current PE ratio of N/A is calculated by dividing its stock price of $29.00 by its TTM earnings per share of -$2.69.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Stoke Therapeutics, Inc.You STOK | $1.8B | N/A | — | -$2.69 |
 Ardelyx, Inc. ARDX | $1.4B | N/A | — | -$0.26 |
 BioCryst Pharmaceuticals, Inc. BCRX | $1.8B | 6.20x | +43.0% | $1.26 |
 Intellia Therapeutics, Inc. NTLA | $1.5B | N/A | — | -$3.81 |
 Novavax, Inc. NVAX | $1.4B | 2.47x | -43.0% | $2.72 |
 Pharvaris N.V. PHVS | $2.2B | N/A | — | -$2.97 |
 Spyre Therapeutics, Inc. SYRE | $4.3B | N/A | — | -$0.45 |
Industry Average 2 peers with valid PE | — | 4.34x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.12 | — | |
2024-12-31 FY2024 | — | $-1.65 | — | |
2023-12-31 FY2023 | — | $-2.38 | — | |
2022-12-31 FY2022 | — | $-2.60 | — | |
2021-12-31 FY2021 | — | $-2.34 | — | |
2020-12-31 FY2020 | — | $-1.56 | — | |
2019-12-31 FY2019 | — | $-1.80 | — | |
2018-12-31 FY2018 | — | $-0.53 | — | |
2017-12-31 FY2017 | — | $-0.24 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Stoke Therapeutics, Inc. (STOK) measures how much investors pay for each dollar of the company's trailing earnings. STOK's current PE ratio of N/A is calculated by dividing its stock price of $29.00 by its TTM earnings per share of -$2.69.
Frequently asked questions
STOK pe ratio · 6 questionsSTOK's current PE ratio is N/A as of 2026-06-09, based on a stock price of $29.00 and TTM EPS of -$2.69. Data sourced from Financial Modeling Prep via STOK's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Stoke Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09